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Almost forty years ago, it was first hypothesized that an increased dietary intake of omega-3 polyunsaturated fatty acids (PUFA) from
fish fat could exert protective effects against several pathologies. Decades of intense preclinical investigation have supported this
hypothesis in a variety ofmodel systems. Several clinical cardiovascular studies demonstrated the beneficial health effects of omega-
3 PUFA, leading medical institutions worldwide to publish recommendations for their increased intake. However, particularly in
recent years, contradictory results have been obtained in human studies focusing on cardiovascular disease and the clinical evidence
in other diseases, particularly chronic inflammatory and neoplastic diseases, was never established to a degree that led to clear
approval of treatment with omega-3 PUFA. Recent data not in line with the previous findings have sparked a debate on the health
efficacy of omega-3 PUFA and the usefulness of increasing their intake for the prevention of a number of pathologies. In this review,
we aim to examine the controversies on the possible use of these fatty acids as preventive/curative tools against the development of
cardiovascular, metabolic, and inflammatory diseases, as well as several kinds of cancer.
1. Introduction
Over the past three to four decades, a considerable body
of literature has been published indicating possible health
benefits of an increased dietary intake of long-chain omega-
3 polyunsaturated fatty acids (LC-omega-3 PUFA). Their
beneficial effects have been reported for a number of disor-
ders, including cardiovascular [1, 2], neurodegenerative [3, 4],
neuropsychiatric [5, 6], and inflammatory diseases [7], as
well as for some cancer types (mainly colorectal, mammary,
and prostatic cancer) [8–10]. During this time period, a
large number of preclinical in vitro and in vivo studies have
been performed which, rather unanimously, demonstrated
the potential of omega-3 PUFA as preventive and therapeu-
tic agents against hypertriglyceridemia, cardiac arrhythmia,
inflammation, and proliferation, and many experimental
studies have succeeded in elucidating and clarifying many of
the biological and molecular mechanisms underlying these
effects [11–17]. Also, for application in humans, consensus
was reached on the efficacy of these fatty acids (FA) in
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the secondary prevention of some cardiovascular diseases,
since the results of a large and well performed clinical
study [18] had clearly and strongly demonstrated beneficial
effects linked to their intake. As a consequence, omega-3
PUFA have been approved as preventive and therapeutic
tools in the management of several cardiovascular disorders,
as well as for treatment of severe hypertriglyceridemia by
a number of health agencies throughout the world, and a
number of guidelines were published recommending omega-
3 PUFA supplementation (see Section 3). Cardiologists and
other physicians began to prescribe them routinely [19].
Moreover, as diet has always been an important topic for
the popular press, recommendations have reached large
segments of population, so that over-the-counter omega-3
PUFA supplements have become the most sold supplements
worldwide [20].
In contrast to this remarkable story of research perfor-
mance and dissemination, many human studies investigating
the effect of an increased intake of omega-3 PUFA against
noncardiovascular diseases were often not in keeping with
data obtained in preclinical studies, and therefore consensus
recommendations have not yet been made regarding the
usefulness of omega-3 PUFA for the cure or prevention of
inflammatory, neoplastic or neurologic disorders.
Some reports question the effectiveness of omega-3
PUFA in cardiovascular prevention [21–24], and others argue
that an increased intake of these compounds could induce
or exacerbate some neoplastic pathologies [25–27]. Where
does this leave the field of omega-3 PUFA research and
application? We will try to address this pertinent question
exploring in Section 2 our body’s need for omega-3 PUFA to
satisfy physiological needs and to prevent the development
of several kinds of diseases, in Section 3 the history and
present status of omega-3 PUFA in cardiovascular diseases, in
Section 4 inflammatory diseases, and in Section 5 colorectal
and prostate cancer. We will describe in each of these
sections the controversies arisen, and in Section 6 we will
consider and critically analyze all the possible reasons for
these discrepancies.
2. Omega-3 PUFA Insufficiency/Deficiency and
Current Recommended Intakes
Alpha-linolenic acid (ALA), an 18-carbon omega-3 essential
FA, is the precursor of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). The term “essential” indicates
that ALA cannot be synthesized by humans and therefore
must be entirely acquired from exogenous sources. Evidence
for the essentiality of ALA was first provided by a study
showing that ALA supplementation reversed the abnormal
neurologic signs observed in a 6-year-old girl who suffered
from sensory loss and visual complications [28]. Following
consumption, most of the ALA is catabolized via 𝛽-oxidation
for energy generation, and a small proportion of it undergoes
conversion to produce another two potent members of
omega-3 PUFA family: EPA and DHA [29]. The conversion
rates of ALA to EPA and DHA in humans are estimated at
8–20% and 0.5–9%, respectively [30]. Owing to the fact that
EPA and DHA can be synthesized in the body from ALA,
these two FA do not meet the definition of essential FA per se.
However, as this conversion is not efficient enough to satisfy
health requirements, EPA and DHA are also considered
essential FA (or conditionally essential FA). In addition,
although not conclusive, the benefits associated with ALA
seem to stem mainly from EPA and DHA, and as major
consequence of ALA deficiency it appears that EPA andDHA
are not adequately produced [31, 32]. The clinical features
of omega-3 PUFA insufficiency include impaired growth,
skin lesions, infertility, kidney abnormalities, fatty liver,
polydipsia, increased susceptibility to infections, reduced
learning, and impaired vision [33, 34]. Yet, these symptoms
are nonspecific and may also result from the dysregulation
in omega-6 PUFA homeostasis [35]. For example, the skin
lesions present in patients with atopic eczema have been
associated with poor omega-6 PUFA intake [36].
An increased intake of omega-3 PUFA, especially the
long-chain omega-3 PUFA EPA and DHA, could reduce
the tissue omega-6/omega-3 ratio to a level that probably
existed duringmillions of years of human evolution [37].This
ratio dramatically increased in recent millennia due to deep
changes in dietary habits following the transition from the
hunter-gatherer lifestyle to agricultural societies.This change
could therefore be one of the crucial factors leading to the
rise of the so-called diseases of civilization, further skewed
towards omega-6 PUFA by the agricultural revolution in
the 19th century and the massive use of corn (with its high
omega-6 PUFA content) in western societies during the 20th
century.
Dietary recommendations for omega-3 PUFA, previ-
ously focused on ensuring their sufficient intake to prevent
deficiency, are increasingly seeking to define an “optimal”
intake to reduce the risk of developing chronic diseases,
in particular cardiovascular diseases (CVD). To date, there
is no uniform scientific guideline on the ideal omega-3
PUFA intake. Nutritional guidelines have been published
by several governments (France, Belgium, Netherlands, New
Zealand, and Australia) and health organizations (Food and
AgricultureOrganization (FAO), AmericanDietetic Associa-
tion).Themost popular recommendations on omega-3 PUFA
intake are those published by theAmericanHeartAssociation
(AHA), the UK Committee on Medical Aspects of Food
Policy, the World Health Organization (WHO), and the
European Food Safety Authority (EFSA). Recommendations
for omega-3 PUFA (ALA, EPA, and DHA, individually or
combined) for adults according to various recently published
dietary guidelines are shown in Table 1, whereas Table 2
shows recommendations for infants and children [38–53].
Dietary recommendations for EPA +DHA range from 250 to
1000mg/day for adults and from 40 to 250mg/day for infants
older than six months and for children and adolescents.
3. Omega-3 PUFA Efficacy in
the Cardiovascular Field
The predominant field of omega-3 PUFA research in the
past decades has been that of cardiovascular medicine and
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Table 1: Recommended dietary intakes for omega-3 fatty acids in adults from national and international organizations.
Region/country Organization, year, reference ALA (g/day) DHA (g/day) EPA + DHA (g/day)
International
FAO/WHO, 2010 [38] 0.25–2.0
ISSFAL, 2004 [39] >0.5
Eurodiet, 2001 [40] 2.0 0.2
WAPM, 2008 [41] 0.2–0.3
EFSA, 2010 [42] 0.25
National
UK SACN, 2004 [43] 0.45
Netherlands Health Council, 2006 [44] 0.45
France ANSES, 2001 [46] 0.25 0.5
0.2
Spain SENC, 2011 [48] 0.5–1.0
Australia NHMRC, 2006 [49] M: 1.3F: 0.8
M: 0.61
F: 0.43
USA
IoM, 2005 [50] M: 1.6F: 1.1
American Diabetes Association, 2007 [51] 2.0 0.2
ADA USA & Canada, 2007 [52] M: 1.6F: 1.1 0.5
AHA, 2009 [53] 0.5–1.0
M: male; F: female.
Table 2: Recommended dietary intakes for omega-3 fatty acids in children from national and international organizations.
Region/country Organization, year Age range ALA (mg/day) DHA (mg/day) EPA + DHA (mg/day)
International
FAO/WHO, 2010 [38]
6–24mo 10–12/kg
2–4 y 100–150
4–6 y 150–200
6–10 y 200–250
EFSA, 2010 [42] 7–24mo 100
2–18 y 250
National
Belgium CSS, 2009 [47] 0–12mo 500
Netherlands Health Council, 2001 [45] 0–5mo 80/kg 20/kg
6mo–18 y 150–200
France ANSES, 2001 [46]
6mo–3 y 70
3–9 y 125 250
10–18 y 250 500
Australia NHMRC, 2006 [49]
1–3 y 500 40
4–8 y 800 55
9–13 y M: 1000F: 800 70
14–18 y M: 1200F: 800
M: 125
F: 85
USA IoM, 2005 [50]
1–3 y 700
4–8 y 900
9–13 y M: 1200F: 1000
14–18 y M: 1600F: 1100
M: male; F: female.
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prevention. This is the field in which the hypothesis of a pro-
tective effect of omega-3 PUFA was founded [69], and a large
clinical study establishing a benefit was the basis for approval
of omega-3 PUFA as secondary prevention in patients after
myocardial infarction [18]. The GISSI-Prevenzione trial was
performed as an open-label trial in the 1990s in 11324
patients shortly after myocardial infarction. Participants in
the omega-3 PUFA group received 1 g/d omega-3 PUFA (ratio
of EPA/DHA 1 : 2, with a total amount of EPA + DHA of
approximately 850mg) for 3.5 years.Therewere no systematic
fatty acid measurements performed in the participants, but,
as an indication of omega-3 PUFA uptake, triglycerides were
lower in the omega-3 PUFA group. Treatment with omega-
3 PUFA significantly lowered the risk of death, including
cardiovascular death [18]. This area has seen some good
examples of translational research, particularly with regard to
the antiarrhythmic effects attributed to omega-3 PUFA. Leaf
[70, 71] was a pioneer in the field of omega-3 PUFA research
showing that these FA can block proarrhythmogenic effects
of adrenal agents, calcium, and other substances in isolated
cardiomyocytes, continuing with studies in animals [72], and
finally concluding his research in a large human multicenter
trial [54]. The concept of cardioprotection through omega-
3 PUFA supplementation has been firmly engrained into
the canon of medical knowledge and clinical thinking, as is
evidenced by the AHA guidelines recommending intake of
omega-3 PUFA [73].
However, while preclinical data regarding the antiar-
rhythmic effect of omega-3 PUFA were strongly beneficial,
the double-blind intervention study by Leaf et al. [54] does
not show a clear benefit. A relevant problem of the study
was the high noncompliance rate (35% of enrollees, similar
in fish oil and olive oil groups), probably due to the high
capsule load (2600mg fish oil per day). Treatment with daily
fish oil or olive oil for 12 months in patients with implanted
cardioverter/defibrillators (ICDs) did not lead to a significant
difference for the primary end point (time to first ICD event
for ventricular tachycardia (VT) or death from any cause).
However, there was a significant effect in participants who
were at risk of fatal ventricular arrhythmias and, after staying
on protocol for at least 11 months, showed a significant risk
reduction of 38%. Phospholipid fatty acid content of red
blood cells was compared in a subset of participants in the
study, and omega-3 PUFA content increased significantly
from 3.4% to 7.6% of total fatty acids, while it remained at
3.5% in the olive oil control group.
There are two more randomized, double-blind, placebo-
controlled trials with omega-3 PUFA supplementation per-
formed in patients with ICDs and at high risk of high-grade
arrhythmic events. In one, 200 patients with an ICD and
a recent episode of sustained VT or ventricular fibrillation
(VF) received either 1300mg/d omega-3 PUFA or placebo
and were followed up for 2 years. While patients on fish oil
had an increase in the mean percentage of omega-3 PUFA in
red blood cell membranes from 4.7% at baseline to a steady-
state maximum of 8.3% at 3 months, there was no protection
from VT/VF events [59]. The third study did not find a
significant advantage for omega-3 PUFA supplementation in
ICD patients receiving 2 g/d of fish oil (𝑛 = 273) versus
placebo (𝑛 = 273) for one year with the primary outcome
of an ICD event or death occurring in 30% patients taking
omega-3 PUFA versus 33% of those on placebo [60].
In addition to these high-quality data sets showing
uncertainty regarding the antiarrhythmic effect of omega-3
PUFA, several large studies followed up on the initial positive
GISSI-P results. The GISSI-HF investigated the effect of 1 g/d
omega-3 PUFA in patients with heart failure in a randomised,
double-blind, placebo-controlled trial with 6975 participants.
Over approximately 4 years there was a small significant
advantage in the omega-3 PUFA group for death from any
cause and admission to hospital for cardiovascular reasons
with a number needed to treat of 56 to prevent one death [55].
A multicenter, double-blind, placebo-controlled trial
with 4837 patients after a myocardial infarction tested 40
months of fatty acid supplementation in the form of mar-
garines, either adding a small amount of approximately
400mg/d EPA + DHA, 2 g/d of ALA, both EPA + DHA and
ALA, or placebo fat. Neither EPA-DHA nor ALA reduced the
primary end point of amajor cardiovascular event. Fatty acids
were measured in plasma cholesteryl esters of subgroups,
and supplementation with EPA + DHA increased EPA by
53.3% and DHA by 28.6%, as compared with placebo after 20
months. Unfortunately, fatty acid composition of red blood
cell membranes was not measured in this study [21].
Another randomized, placebo-controlled, double-blind,
multicenter trial in 3851 patients with 1 g/d omega-3 PUFA
supplementation for one year in patients after acute myocar-
dial infarction also demonstrated no benefit of omega-3
PUFA [58].
A third large study with 2501 participants found that
administration of 600mg/d omega-3 PUFA increased plasma
concentrations of EPA+DHAby 37% comparedwith placebo
but also had no significant effect on major vascular events
in patients with ischaemic heart disease or ischaemic stroke
[56].
Based on these and several smaller intervention studies
assessing mostly relatively low-dose omega-3 PUFA supple-
mentation, two thorough metastudies concluded that there
is no convincing evidence for a preventive effect of omega-3
PUFA in patients with cardiovascular disease [22, 62].
TheORIGIN study [23] is themost recent large study that
failed to show a clear benefit of omega-3 PUFA supplemen-
tation for cardiovascular health. This study, conducted in a
patient population with dysglycemia, led many physicians to
conclude that the relationship between dietary omega-3 and
cardiovascular health needs to be viewed with caution. In this
double-blind study 12536 dysglycemic patients at high risk
for cardiovascular events were assigned to either 900mg/d
omega-3 PUFA or placebo. The primary outcome was death
from cardiovascular causes during a median follow-up of 6.2
years, and there were no significant differences between the
two treatment groups for this primary parameter as well as
for a range of secondary parameters. It is noteworthy that the
significant decrease of triglycerides is an indicator of effective
omega-3 PUFA exposure in the verum group. However,
unfortunately, fatty acid levels in the blood, particularly in the
red blood cell fraction, were not evaluated.
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Nutritional research, especially the clinical trials investi-
gating different dietary regimes, has always been surrounded
by controversy. The role of dietary fat in obesity and associ-
ated clinical conditions is a prime example [74], with ongoing
uncertainty about the role of a low-fat diet in the battle
against cardiovascular disease [61]. Recent recommendations
by the AHA and the medical bodies in the US acknowledged
also a protective effect of the omega-6 PUFA [53], and more
studies have added complexity and controversy to the role of
different FA classes (saturated fats,monounsaturated olive oil,
polyunsaturated omega-6, and omega-3 PUFA), challenging
not only the hypothesis of beneficial effects associated with
unsaturated fatty acids but also the paradigmof the damaging
effects of saturated fatty acids [61, 75].
What can we learn from all this regarding the potential
cardiovascular benefits of omega-3 PUFA? It is difficult from
today’s perspective to adequately assess the conditions of
the 70s observations regarding the omega-3 effects in the
Greenland population, and the arguments of inadequate data
validity in these studiesmade by Fodor et al. [24] are plausible
giving the remoteness of many Greenland communities and
problems with medical service and adequate documentation
in these areas.
While the protective cardiovascular effect of omega-3
PUFA was not detected in several large recent high-quality
studies, there are particularly two high-quality intervention
studies, both of them open-label studies though, showing a
clear benefit of omega-3 PUFA, the GISSI-P study [18] and
the JELIS study demonstrating a protective effect of an EPA
preparation combined with a statin medication [57]. This
large open-label study performed on 18645 Japanese patients
assigned them to randomly receive either 1800mg/d of EPA
daily plus statin or statin only. The primary endpoint of a
major coronary event was significantly reduced in the EPA
groupwith a 19% relative reduction.However, sudden cardiac
death and coronary death did not differ between the groups.
Plasma EPA was measured in this study and in patients
still on supplement after 5 years of observation plasma EPA
concentration was increased by 70% in the EPA group.
In conclusion, many high-quality preclinical (observa-
tional as well as interventional) and clinical studies have been
performed to assess the potential cardiovascular benefit of
omega-3 PUFA. A recent large metastudy has again analyzed
and summarized these studies and found no clear benefit of
omega-3 PUFA to protect from coronary artery disease in
observational studies as well as in randomized, controlled
trials [61]. This metastudy also explored the role of other
fatty acids and concluded that the current evidence does not
clearly support cardiovascular guidelines encouraging either
high consumption of omega-3 or omega-6 PUFA, or even low
consumption of saturated fats.
Cardioprotective effects of dietary omega-3 PUFA might
be confounded by the use of cholesterol-lowering medica-
tions: in the GISSI-P study only 5% of participants were on
a cholesterol-lowering drug [18], which is in strong contrast
to the ORIGIN omega-3 PUFA study, where approximately
half the patients were on a statin [23]. Statins have been
hypothesized to interfere with the protective effect of omega-
3 PUFA [76].
Modifications in the observed omega-3 effects might also
be due to changes in the diet over the last 30–40 years, in
which the hypothesis of omega-3 PUFA as beneficial dietary
components has been propagated, and therefore background
levels of omega-3 PUFA in the participants of more recent
studies might be higher than several decades ago. This
should be addressable by (comparable) measurements of
omega-3 PUFA that, unfortunately, have been performed
only sporadically in the studies carried out to date. Baseline
omega-3 PUFA levels are lacking from most of the discussed
large studies investigating omega-3 PUFA interventions. Sev-
eral studies have suggested that erythrocyte EPA and DHA
content (measured by a certifiedmethod as “omega-3 index”)
may better reflect the omega-3 PUFA status in patients
than measurement in plasma and white blood cells [77, 78],
and the low omega-3 index was described to be associated
with higher mortality in patients with cardiovascular disease.
However, so far, there has been no single well-accepted and
uniformly performed blood test for the omega-3 PUFA status
in human studies, complicating the comparison and inter-
pretation of different studies. The current state of evidence
for the effects of omega-3 PUFA in human studies regarding
cardiovascular diseases and the contrasting outcomes have
been summarized in Table 3. Additional possible reasons for
the controversies in the field are reported in Section 6.
Last but not least, it should be noted that the effect of
omega-3 PUFA in the cardiovascular field can also be viewed
in the context of their role as precursors of highly potent phys-
iologically beneficial lipid mediators [79, 80]. A cytochrome
P450 epoxygenase-dependent metabolite of EPA, namely,
17(R),18(S)-epoxyeicosatetraenoic acid (17(R),18(S)-EETeTr),
was found to exert negative chronotropic effects and can
protect neonatal rat cardiomyocytes against Ca2+-overload
[81]. Another EPA-metabolite, 18-hydroxyeicosapentaenoic
acid (18-HEPE), was recently shown to inhibit macrophage-
mediated proinflammatory activation of cardiac fibroblasts
in vitro, while in vivo administration of 18-HEPE led to
resistance to pressure overload-induced maladaptive cardiac
remodeling in mice [82].
4. Omega-3 Efficacy in Inflammatory Diseases
Research data accumulated to date indicate that omega-6
PUFA play a significant role in the biology of inflammation.
Work on the biochemistry of omega-6 led to the identification
of prostaglandins and leukotrienes as key players in the
physiology of inflammation [118]. Moreover, this work elu-
cidated the cascade of the molecular mediator system arising
from the omega-6 PUFA arachidonic acid and led to mech-
anistic understanding and further development of the most
widely prescribed drug class worldwide, the cyclooxygenase-
(COX-) inhibitors [119].
Early work on omega-3 PUFA identified the antagonism
between omega-6 and omega-3 PUFA. It was postulated that,
by competitive inhibition of COXand other enzymes, omega-
3 PUFA could serve as anti-inflammatory agents. Indeed, it
has been found that a high omega-3 intake was associated
with a lower risk of inflammatory disease mortality [120].
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Table 3: Current state of evidence for the effects of omega-3 PUFA in published human intervention studies regarding cardiovascular disease.
Type of study Beneficial effect Beneficial effect limited tosubpopulation
Detrimental
effect No effect
Clinical trials
Lower risk of
cardiovascular events and
death with open-label
omega-3 PUFA treatment
(850mg/d) [18]
High-dose omega-3 PUFA
intervention in ICD
patients at high risk of
arrhythmia—significant
protection in patients
treated per protocol for 11
months [54]
Administration of 900mg/d omega-3
PUFA in dysglycemic patients at
increased cardiovascular risk had no
protective effect [23]
Lower risk of death in
patients with heart failure
on 1 g/d omega-3 PUFA
[55]
No decrease in major cardiovascular
events in patients on 500mg/d
omega-3 PUFA [56]
Cardioprotective effect of
open-label EPA
supplementation in
addition to a statin in
hypercholesterolemic
patients [57]
Administration of 1 g/d omega-3 PUFA
in patients after a myocardial
infarction showed no benefit [58]
No reduction in cardiovascular events
in patients after myocardial infarction
with either 400mg/d EPA + DHA or
2 g/d ALA, or both [21]
No VT/VF protection in ICD patients
on 1300mg/d omega-3 PUFA [59]
No arrhythmia protection in ICD
patients on 2 g/d fish oil [60]
Meta-analyses
Current data do not support the
concept of increasing omega-3 PUFA
or omega-6 PUFA or decreasing
saturated fatty acid intake, to reduce
cardiovascular risk [61]
No benefit of omega-3 PUFA
supplementation in 14 randomized
double-blind placebo-controlled
studies [22]
No benefit of omega-3 PUFA
supplementation in randomized
clinical trials assessing cardiovascular
endpoints [62]
ICD: implanted cardioverter/defibrillator; VF: ventricular fibrillation; VT: ventricular tachycardia.
Many animal studies demonstrated the anti-inflamma-
tory effect of omega-3 PUFA. As far as animal models of
colitis are considered, EPA-ethyl or DHA-ethyl ester sup-
plementations (1% w/w in the diet, given for 10 days prior
to treatment) were reported to reduce colitis obtained in
dextran sodium sulfate- (DSS-) treated mice [121], as demon-
strated by their ability to inhibit the expression of several
proinflammatory cytokines. Similar results were obtained
also by supplementing a FO enriched diet (concentration
not specified, dietary n:6/n:3 ratio: 1.5, for 7–11 weeks) in a
severe combined immunodeficient mouse model of colitis
[122]. In agreement with that, a FO enriched diet (containing
1% FO providing 0.5 g EPA + DHA g/day, for 5 weeks prior
to infection) was shown to attenuate infection-induced colitis
in mouse infected with Citrobacter [123]. Furthermore, also
a parenteral lipid emulsion enriched in omega-3 PUFA (10%
FO, 0.5mL/h for 7 days) was found to reduce acetic acid-
induced colitis in rats [124].
However, opposite results have also been obtained and
extensively and recently reviewed by Fenton et al. [125]. In
particular, dietary FO (8% w/w in the diet, for 5 weeks,
starting one week prior to treatment) was shown to increase
DSS-induced colitis [126]. Moreover, diets containing 2.25–
6.00% FO (containing 59% DHA + EPA, for 8 weeks
after infection) were recently found to induce severe colitis
and epithelial dysplasia in mice infected with Helicobacter
hepaticus [127]. Furthermore, FO (7% FO w/w in the diet,
for 12 weeks) was found to exacerbate colitis and colitis-
associated premalignant lesions [128] in IL-10 −/− trans-
genic mice, spontaneously developing enterocolitis [129].
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In contrast, Chapkin et al. [130] showed that a FO enriched
diet (4% FO w/w in the diet, for 10 weeks) fed to the same
IL-10 −/− transgenic mice reduced the clinical score of both
spontaneous and NSAID-induced colitis.
Interestingly, however, when at least the uncertainty
related to variable intakes of FO was overcome by using
the Fat-1 mouse model of endogenously increased omega-
3 PUFA [131], the inflammation-dampening effect of an
increased omega-3 PUFA tissue content was consistently
observed in the murine models of DSS-induced colitis [132,
133]. Moreover, when Fat-1 mice were also treated with the
carcinogen azoxymethane prior to DSS, an enhanced ability
to resolve colitis and a reducednumber of colonic adenocarci-
nomas permousewere observed [134, 135]. In theFat-1mouse
model a reduced D-galactosamine/lipopolysaccharide- (D-
GalN/LPS-) induced hepatitis [136] and cerulein-induced
pancreatitis [137] were also observed.
As concluded by Fenton et al., it is particularly in the
context of studies with infectious agents that deleterious
effects of omega-3 PUFA were observed [125], and these
authors argue that the same (auto)inflammation-dampening
and cardioprotective properties of the omega-3 PUFA might
be responsible for an ineffective immune response against
pathogens and even decreased immune surveillance against
tumor cells. However other data do not support this view of
a uniformly immunosuppressant effect of omega-3 PUFA: a
recent study shows that omega-3 PUFA can actually increase
B-cell function and thus humoral immunity [138].
Also the clinical data from intervention trials with
omega-3 appear to be controversial. Initial results in Crohn’s
disease and ulcerative colitis [63, 66] found a benefit. How-
ever, later studies showed a negligible impact of omega-3
PUFA on the relapse rate in Crohn’s disease [65] as well
as in ulcerative colitis; the studies performed in inflam-
matory bowel disease are reviewed in a recent metastudy,
concluding that total data quality so far is insufficient for
clear recommendations [68]. Data from acute pancreatitis in
humans indicated some benefits [67]; however, there are no
data from chronic pancreatitis, and the recently published
Welcome Trial data regarding the use of omega-3 PUFA
in nonalcoholic steatohepatitis (NASH) do not show an
overwhelming benefit of supplementation in the intention-
to-treat (ITT) analysis, even though there was a statistically
significant linear correlation between decreased liver fat
content and increased DHA enrichment [64]. The current
state of evidence for the effects of omega-3 PUFA in human
studies regarding inflammatory diseases and the contrasting
outcomes have been summarized in Table 4. Possible reasons
for the controversies in the field are reported in Section 6.
Experimental data from recent years are currently reshap-
ing omega-3 PUFA research: since the initial description of
resolvins [139] and the characterization of resolvin E1 [140], a
wealth of data on this new class of omega-3 PUFA-derived
lipid mediators has been published (reviewed in [80]). It
is now clear that omega-3 PUFA not only play a role as
competitive antagonists of the COX and lipoxygenase (LOX)
enzymes, but also are substrates for potent lipid mediators
themselves. It has been shown that a high abundance of these
FA as substrates can significantly change the lipidome and
eicosanome, given that they are efficientlymetabolized aswell
[79]. For the DHA-derived D-resolvins, 17-HDHA has been
characterized as a central pathway precursor/metabolite, and
for the EPA-derived E-resolvins, 18-HEPE serves this role.
Data from one of the authors have indicated that these
might have anti-inflammatory properties themselves [141–
143]. Other groups have described the effects of 17-HDHA
as well [144–146], and very recently an independent role
of 18-HEPE was also demonstrated in the context of a
cardiac fibrosis model [82]. This is currently a very active
field of research and will probably give us new tools for
understanding the effects of omega-3 PUFA in the context
of inflammation dampening, as well as a number of new
leads for pharmacological compounds that could be used
to mediate anti-inflammatory effects in the future. As these
compounds can promote resolution of inflammation [147],
this could lead to an entirely new approach to the treatment
of chronic inflammation in the future.
Closely related to these effects regarding inflammation
dampening are the experimental data regarding tumorigen-
esis. One of us and his group have validated a tumorigenesis
inhibiting effect in the Fat-1mousemodel with endogenously
increased omega-3 PUFA for liver cancer [143] and colon
cancer [135]; this fits well with data from other groups
employing the Fat-1mouse model [134, 148, 149].
Particularly in gastrointestinal medicine, the paradigm
of inflammation-associated carcinogenesis is central. It holds
true for the development of esophageal carcinoma on the
basis of Barrett’s esophagus, stomach cancer on the basis of
chronic H. pylori infection, liver cancer as a consequence
of chronic hepatitis, cholangiocellular cancer in chronic
cholangitis, pancreatic cancer as a consequence of chronic
pancreatitis, and also in colorectal cancer. There are clinical
data supporting the tumorigenesis inhibiting effect of omega-
3 PUFA in the gastrointestinal tract, either with regard to
colon cancer and the lowering of polyp formation in the colon
[83, 90, 91] or with regard to hepatocellular carcinoma [150].
It is therefore conceivable that increasing omega-3 PUFA
intake could be established as an easy and low-risk, high-
gain intervention for the prevention of tumorigenesis. Given
the very low risk of severe adverse events in comparison to
interventions such as the use of theCOX-inhibitor aspirin, for
which similar antitumorigenesis effects are well established
by now [151, 152], omega-3 PUFA supplementation becomes
an attractive perspective. An ongoing study is even testing the
combination of EPA and aspirin for the prevention of colon
polyps [153].
5. Omega-3 Efficacy in Cancer
5.1. Mechanisms Involved in Omega-3 PUFA Anticancer
Action. Most of the studies performed either in vitro or using
animal models of cancer have demonstrated the possible
preventive and therapeutic role of omega-3 PUFA against
several types of cancer. These studies have also shed light on
multiple molecular pathways modulated by these fatty acids
in cancer cells and implicated in the regulation of several
cell processes involved in cancer development and pro-
gression, such as cell proliferation, survival, differentiation,
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Table 4: Current state of evidence for the effects of omega-3 PUFA in human studies regarding gastrointestinal inflammatory conditions.
Type of study Beneficial effect Beneficial effect limited tosubpopulation
Detrimental
effect No effect
Clinical trials
Reduced rate of relapse with 2.7 g/d
omega-3 PUFA in patients with
Crohn’s disease in a double-blind
placebo-controlled study in 78
patients [63]
Decreased liver fat content
with increased DHA
enrichment in NASH
patients [64]
Randomized, double-blind,
placebo-controlled
treatment with approx.
4 g/d omega-3 PUFA did
not prevent relapses in
patients with Crohn’s
disease [65]
Improvements in histologic findings
and weight gain in 18 ulcerative
colitis patients on 5 g/d EPA + DHA
in a randomized double-blind
placebo-controlled crossover trial
[66]
Shortened hospital stay in an
open-label randomized prospective
study administering 3.3 g/d enteral
fish oil in patients with acute
pancreatitis [67]
Meta-analyses
Current data are not
sufficient to support the
concept of omega-3 PUFA
supplementation for the
treatment of inflammatory
bowel disease [68]
NASH: nonalcoholic steatohepatitis.
invasion, and angiogenesis. Actually, it is quite astonishing
how many signaling pathways and molecular targets have
been so far implicated in the antineoplastic effects of these
dietary compounds [8, 15, 154–156]. However, it has been
hypothesized that these fatty acids may more directly act
through just a few main direct routes and consequently
influence the activity/expression/levels of plenty of cellular
pathways and molecules more or less specifically altered in
the different cancer tissues. Actually, the topic concerning the
mechanisms underlying the omega-3 PUFA antineoplastic
action is very complex and beyond the focus of this review.
Several exhaustive reviews have been previously written by us
and others that critically analyzed the possible cell signaling
pathways involved in omega-3 antineoplastic action. The
readers may refer to them to have a more complete view
[8, 15, 154–159].
Nevertheless, the main direct routes through which
omega-3 PUFA are hypothesized to more directly act are
worth mentioning here. One of these routes is related to
the omega-3 PUFA increased incorporation in cell mem-
branes, as it happens consequently to their increased dietary
intake. As a result, physical-chemical alterations of molecular
lipid microenvironments (rafts) take place on cell surface
[160]. These modifications may in turn lead to changes in
the activity/expression of membrane constituents (recep-
tors, channels, enzymes, adapter proteins, etc.) and multiple
molecular pathways placed downstream. For instance, it was
recently observed [121] that the incorporation of DHA in
immortalized colonocytes in vitro altered the lateral orga-
nization of the Epidermal Growth Factor Receptor (EGFR),
thus leading to increased ligand-induced receptor dimer-
ization and phosphorylation along with its internalization
and degradation. These changes, in turn, resulted in the
disruption of the EGFR-Ras-ERK1/2 signaling cascade and
the inhibition of cell proliferation. Accordingly, in chronically
inflamed, carcinogen-injected mice, these authors found that
a DHA-enriched diet induced the same effects observed in
vitro on the EGFR signaling pathway and also inhibited
tumor development. Similarly, we recently found [161] that
DHA could dislocate from colon cancer cell surface the
antiapoptotic Glucose Related Protein of 78 kDa (GRP78),
abnormally expressed on cancer cells plasma membranes
[162], where it acts as a signaling receptor promoting prolifer-
ation and survival. Through this mechanism, DHA inhibited
the ERdj5/PERK/caspase-4 and caspase-7 pathway placed
downwards and induced apoptosis [161].
A second main possible direct route for the omega-3
PUFA action is related to their high peroxidability that makes
them optimal substrates for oxidants inside the cells [163].
Through this route, these fatty acids may induce alterations
of the cell oxidative status andmodulation of oxidative stress-
dependent molecular pathways related to cell proliferation,
apoptosis, or inflammation.
Moreover, a thirdmain direct route for the omega-3 PUFA
action is related to their possible metabolic conversion into
bioactive molecules with powerful anti-inflammatory and
proresolving action (i.e., resolvins, protectins, etc.). Receptors
binding specifically to both these bioactive molecules (such
as ChemR23, leukotriene B4 receptor 1, LTB4R1, and G
protein coupled receptor, GRP32) [164] as well as to omega-3
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PUFA (such as peroxisome proliferator activated receptor
𝛾, PPAR𝛾, and G protein coupled receptor, GPR120) have
been recently identified [164, 165]. The signaling starting
from these receptors may be translated downwards into the
induction of specific cellular molecular pathways.
Finally, a very interesting possibility that may represent
the field of future promising investigation in this research area
is that omega-3 PUFA, through one or more of these main
direct routes, may in turn affect DNA cytosine methylation,
the covalent modifications of histones, or the expression of
noncoding microRNA (miRNA). These effects may alter the
epigenetic control of genes codifying proteins involved in cell
proliferation and survival. It has been already hypothesized
that alterations of epigenetic control of gene expression could
be involved in the beneficial effects that omega-3 PUFA exert
in immunological or neurodegenerative diseases [166–168] or
in some kinds of cancer [157, 169–171].
5.2. Omega-3 PUFA in Colon Cancer. Dietary omega-3 PUFA
have attracted considerable interest for their potential to
prevent the development and progression of colorectal cancer
(CRC) [8, 158, 172]. An impressive body of evidence has been
obtained in preclinical studies using in vivo CRC models,
consistently supporting the antineoplastic role of omega-3
PUFA [8, 154, 172], in spite of the high variability of the
models and experimental conditions used [134, 135, 154, 173,
174]. Among all these data only very few were in conflict with
a protective effect of the omega-3 PUFA [127, 175], but in
these cases extremely high doses of LC-omega-3 PUFA were
administered (about 3–7 g EPA + DHA/kg body weight in
mouse or 12 g EPA + DHA/kg body weight in rat; for the
calculation used, see [216]). These high doses may generate
vast amounts of oxidized products with high prooxidant and
carcinogenic activity [26].
Many in vitro studies [8, 154, 172] confirmed the anti-
neoplastic activity of omega-3 PUFA and, as discussed in the
previous section, allowed identification of possible biological
and molecular mechanisms [154]. Remarkably, among the
in vitro studies [176–178] are those that recently investigated
the possible effects of omega-3 PUFA on colorectal cancer
stem cells (CCSC). It is believed that CCSC may drive colon
tumorigenesis, being principal targets of tumorigenic genetic
alterations, due to their long lifespan and capacity for self-
renewal. Moreover, they have also been related to cancer
relapse, acquisition of chemotherapy resistance, andmetasta-
sis [179]. CCSC are characterized for lacking specific markers
of colonic epithelium differentiation, such as cytokeratin 20
(CK20) or mucin 2 (MUC2), and expressing instead specific
clusters of differentiation, such as CD133 or Lgr5 antigens
(labeling undifferentiated cells) [180–182]. Moreover, most
of cancer stem cells form spheres when cultured in serum-
free conditions that are highly tumorigenic if injected in
immunodeficient mice [176, 178]. Yang et al. [176] cultivated
cancer stem-like cell spheres derived from SW620 colon
cancer cell line and showed that both EPA and DHA (10–
70 𝜇M) inhibited their growth by inducing apoptosis and
that the effect was markedly increased when they acted
simultaneously. Moreover, EPA and DHA enhanced the
efficacy of chemotherapeutics agents such as 5-fluorouracil
(5-FU) and mitomycin C. Instead, de Carlo et al. [177] found
that whereas 25 𝜇M EPA inhibited the growth of the COLO
320 DM colon cancer cell line in vitro, it was unable to
inhibit that of its CD133+ subpopulation. However, EPA
upregulated CK20 and MUC2 and downregulated CD133
expression, thus indicating that it triggered the transition of
CCSC to a more differentiated cancer cell phenotype. The
authors hypothesized that the increased degree of CCSC
differentiation induced by EPA could be strictly related to the
EPA-induced sensitization of CD133+ cells to the anticancer
agent 5-FU that they observed. Accordingly, Vasudevan et al.
[178] found that EPA alone and especially in combination
with 5-FU + oxaliplatin (FuOX) was effective in inhibiting
cell growth and sphere formation, as well as in inducing
apoptosis of (FuOX-) resistant HT-29 and HCT116 CRC,
highly enriched in CCSC.
The confirmation in different experimental settings [176–
178] that omega-3 PUFA can increase the sensitivity of colon
CCSC to conventional antineoplastic drugs is very interest-
ing, since, as reviewed by us and others previously [183–185],
the most feasible potential anticancer application for these
fatty acids in humans will be their possible use as adjuvants—
to help increase nutrition status, as well as affort/modulate
anticancer effects—in combination with conventional or
single-targeted anticancer therapies.
If we turn to consider the interventional studies con-
ducted on healthy volunteers, CRC patients, or subjects at
high risk for CRC, the majority of them have concurred to
demonstrate the beneficial antineoplastic effect of omega-3
PUFA (Tables 5(a) and 5(b)).The first studies were performed
about twenty years ago by supplementing purified EPA +
DHA or fish oil (FO).They demonstrated the efficacy of these
FA in inhibiting abnormal CRC cell proliferation [83–85, 87],
when given either in higher amounts (daily dose: 8-9 g EPA +
DHA) for short (2 weeks) and longer periods (3–6 months)
or in lower amounts (daily dose: 2.5–4 g EPA + DHA) after
one month [85]. However, when the same treatment was
performed in the presence of a basal high-fat diet and a low
omega-3/omega-6 PUFA ratio of 0.25, no effect on rectal
mucosa cell proliferation was observed [86], confirming that
the efficacy of omega-3 PUFA is dependent on both the total
lipid content and the omega-3/omega-6 PUFA ratio of the
diet. Also Gee et al. [88] did not find any change in cell
proliferation by administering 2.4 g/day EPA + DHA for 3
months, but in this case there is no available information on
basal diet or dietary omega-3/omega-6 PUFA ratio. Instead,
Cheng et al. [89], who treated patients at high risk for CRC
with lower doses (as FO, about 500mg EPA +DHA/day), but
for a very long period (2 years), observed apoptosis induction
in the mucosa adjacent to the resected CRC [89]. More
recently, Courtney et al. [90] administered gastroresistant
capsules containing EPA-free fatty acid (FFA, 2 g/day) and
confirmed the inhibition of cell proliferation and induction
of apoptosis in colonic mucosa of subjects at high risk for
CRC cancer. The same treatment was recently shown [91]
to reduce the number and size of rectal polyps in familial
adenomatous polyposis (FAP) and to inhibit angiogenesis in
patients carryingCRC livermetastases [92]. A largemulticen-
ter trial (seAFood Polyp Prevention Trial) [153] is now being
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conducted, supplementing the EPA-FFA formulation alone
or in combination with aspirin to patients at high risk for
developing colorectal adenomas. It would be interesting also
to study the effect of DHA in the same formulation, since
antineoplastic activities have also been reported for both fatty
acids [155]. Moreover, even though EPA can be metabolically
converted into DHA and DHA retroconverted into EPA, the
in vivo efficiency of these two metabolic reactions may be
substantially different [186].
The outcomes of the recent large multicentric interven-
tional FISHGASTRO study [93, 94] showed that an extra
300 g/week fish serving for 6 months lowered significantly
the serum C-Reactive Protein (CRP) concentration in all the
subjects, but it did not alter the levels of several inflammation
markers in fecal water and colonic biopsies or change the
apoptotic rates in colonic mucosa. However, the mitotic rate
decreased in the fish groups, even though the significance
was not attained [93]. Still, it is possible to hypothesize
that the small extra supplementation on top of an already
large amount of fish consumed at baseline (corresponding
to about 0.09 or 1.4 g EPA + DHA/day) was not sufficient
to induce significant alterations in mucosal cell growth and
survival. The reduction in serum CRP levels was confirmed
in a recent trial conducted by Mocellin et al. [95] in CRC
patients treated daily with FO containing 0.6 g EPA + DHA,
supporting a general anti-inflammatory effect of omega-3
PUFA supplementation.
After more than twenty years of intense research, several
meta-analyses and systematic reviews of the literature have
been recently published on this topic. If we take into account
only themost recent ones [100–102], their conclusions appear
not to be in agreement.Gerber [102] updated the observations
of the previous meta-analysis conducted by the FAO/OMS
experts [101] to April 2011 and prudently concluded that
overall, owing primarily to insufficient homogeneity of the
observations, the studies analyzed provided only limited evi-
dence suggesting a role for omega-3 PUFA inCRCprevention
[102]. Wu et al. [100] considered in their meta-analysis 22
prospective cohort and 19 case-control studies performed
until 2011.Theymore decidedly concluded that fish consump-
tion was inversely associated with CRC. In particular, they
found a significant inverse association between fish intake
and rectal cancer and only a modest trend between fish
consumption and colon cancer.
Since then, several other case-control and cohort studies
were published. In their case-control studies, Murff et al.
[96] and Habermann et al. [99] demonstrated an inverse
association between an increased omega-3 PUFA dietary
intake and the risk of developing colorectal neoplasms
(adenocarcinomas or adenomas) [96, 99]. However, benefits
were limited only to some of the subpopulations investigated.
In particular, Murff et al. [96] showed that an increased
omega-3 PUFA intake was associated with reduced risk of
colorectal adenomas in women only, whereas Habermann et
al. [99] found that an inverse association between low DHA
intake and increase in CRC risk was confined to patients
showing specific genetic variants that resulted in higher levels
of proinflammatory mediators.
Recent cohort studies found associations only in subco-
horts. Kantor et al. [97] found an inverse association between
FO use and cancer risk, but only at the level of the colon
(not rectum) and only in men (not in women). Moreover, the
same authors [97] found that fish consumption or EPA/DHA
intake was not associated with CRC risk overall but that
associations were significantly modified by genetic risk, with
inverse associations among low-moderate genetic risk groups
and positive associations among high risk groups.The cohort
study of Song et al. [98] found no association between
fish/omega-3 PUFA intake and overall CRC incidence. In
contrast with the Kantor et al. study [97], Song et al. [98]
found an inverse association between a high LC-omega-3
PUFA consumption and rectal cancer (but not colon cancer)
and even a positive association between LC-omega-3 PUFA
increased intake and distal colon cancer.
The controversial findings in epidemiological studies now
need clarification in the setting of large randomized clinical
intervention trials, such as the one currently ongoing [153].
The current state of evidence for the effects of omega-3
PUFA in human studies regarding colorectal cancer and
the contrasting outcomes have been summarized in Table 6.
Possible reasons for the controversies in the field are reported
in Section 6.
5.3. Omega-3 PUFA in Prostate Cancer. Recently, Brasky et
al. [25] suggested a potential prostate cancer promoting effect
of omega-3 PUFA, leading to a new round of discussions on
the effects of omega-3 PUFA in prostate cancer [26, 187–195].
Even though many researchers hold the view that omega-3
PUFA intake is beneficial in this cancer type, the association
between omega-3 PUFA and prostate cancer risk is not
without controversy. On one hand, a case-control study with
3141 participants in Canada provided an inverse association
between fish consumption and prostate cancer incidence and
subsequently suggested that fish consumption may reduce
the risk of developing prostate cancer [103]. Accordingly, a
study focusing on aggressive prostate cancer also found that
a high intake of omega-3 PUFA was strongly associated with
a decreased risk of aggressive prostate cancer, and the odd
ratio (OR) for prostate cancer comparing the highest with the
lowest quartile of omega-3 intake was 0.37 (0.25–0.54) [106].
Moreover, Szymanski’s meta-analysis showed an association
between fish consumption and a significant 63% reduction in
prostate cancer-specific mortality [116]. Chavarro et al. found
that, compared to prostate cancer patients who consume fish
less than once a week, patients who consume at least 5 times
more fish per week had a 48% lower risk of prostate cancer
death [108]. Torfadottir et al.’s study [110] on Icelanders found
a negative correlation between risk of advanced prostate
cancer andFOconsumption in later life.Due to daily intake of
omega-6 PUFA from the diet, the role of the omega-6/omega-
3 PUFA ratio has also been considered. Williams et al. [104]
found that the ratio of dietary omega-6/omega-3 PUFA was
significantly associated with increased risk of high-grade, but
not low-grade prostate cancer. Moreover, it has also been
found [196, 197] that omega-3 PUFAor a low ratio of omega-6
to omega-3 PUFA could decrease the proliferation of prostate
cancer cells in cell culture experiments. Based upon these
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Table 6: Current state of evidence for the effects of omega-3 PUFA in published human studies regarding colorectal cancer.
Type of study Beneficial effect Beneficial effect limited tosubpopulation
Detrimental effect
limited to
subpopulations
No effect
Clinical trials
Antiproliferative effect
[83–85, 87, 90]
No antiproliferative
effect [86, 88, 93, 94]
Proapoptotic effect [89, 90] No proapoptoticeffect [93, 94]
Reduced polyp number and
size in FAP [91]
No anti-inflammatory
effect in colony
biopsies [93, 94]
Reduced angiogenesis [92]
Reduced CRP levels in
serum [93–95]
Observational
studies
Inverse association between
increased dietary intake and risk
of CR adenomas (only in
women) [96]
Positive associations
between FO use and
CRC in high risk groups
[97]
Inverse association between FO
use and cancer risk (in men, not
in women; in colon, not in
rectum) [97]
Positive association
between increased
intake and distal CC [98]
Inverse associations between FO
use and CRC in low-moderate
genetic risk groups, and positive
associations among high risk
groups [97]
Inverse association between
increased intake and RC (but not
CC) [98]
Inverse association between
increased dietary intake and risk
of CRC (only in specific genetic
variants) [99]
Meta-analyses
Significant inverse
association between fish
consumption and RC [100]
Limited evidence of a
role in CRC
prevention [101, 102]
CC: colon cancer; CRC: colorectal cancer; CRP: C-Reactive Protein; FAP: familial adenomatous polyposis; FO: fish oil; RC: rectal cancer.
association observations and considerable amounts of in
vivo and in vitro experimental evidence [198, 199], several
mechanistic hypotheses have been proposed to explain these
phenomena. In particular, as already described in detail in
Section 5.1, PUFA can be converted into many bioactive
metabolites, which play various roles in modulating cell
proliferation, apoptosis, and immune regulation.Many of the
metabolites derived from omega-6 arachidonic acid (AA),
including prostaglandin E2 and leukotriene B4, were shown
to stimulate prostate cancer [200, 201].
On the other hand, several other studies did not provide
evidence of a protective role of omega-3 against prostate
cancer. Kristal et al.’s study [107] suggested that there was
no association between omega-3 PUFA intake and prostate
cancer risk. Brouwer’s meta-analysis showed that the status of
EPA or DHA did not associate with prostate cancer risk [117].
Park et al. [109] found no significant association between
erythrocyte membrane omega-3 PUFA (EPA, DPA, or DHA)
and total or advanced/high-grade prostate cancer risk. In
Mannisto’s study among male smokers [111], no association
between serum EPA or DHA and prostate cancer risk was
found. Harvei et al. [115] could not identify a clear association
between prostate cancer risk and total serum phospholipid
(PL) omega-3 PUFA either. A study based on the 2003–
2010 National Health and Nutrition Examination Survey
(NHANES) [114] found no association between omega-3
PUFA intake and prostate-specific antigen (PSA) level. Chua
et al. [112] found that a high blood docosapentaenoic acid
(DPA) level was negatively associated with total risk of
prostate cancer. In contrast, a significant positive association
between EPA or DHA and high-grade prostate cancer was
shown [112]. Similarly, Sorongon-Legaspi et al.’s study [113]
showed that DPA blood level was negatively linked with total
prostate cancer risk and high EPA andDHAblood levels were
associated with high-grade prostate cancer risk. Crowe et al.
[105] described a positive association between EPA and risk
of only high-grade prostate cancer, while DHA could not be
linked to risk of any stages of prostate cancer.
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Table 7: Current state of evidence for the effects of omega-3 PUFA in published human studies regarding prostate cancer.
Type of study Beneficial effect
Beneficial effect
limited to
subpopulations
Detrimental effect
limited to
subpopulations
No or detrimental effects
Observational
studies
Inverse association between
fish consumption and
cancer incidence [103]
Dietary
omega-3/omega-6
PUFA ratio inversely
associated with risk of
high-grade cancer
[104]
Positive association
between EPA and risk of
only high-grade cancer
[105]
Dietary omega-3/omega-6
PUFA ratio not associated
with risk of low-grade
cancer [104]
Inverse association between
high intake and risk of
aggressive cancer [106]
Positive association
between high serum PL
LC-omega-3 PUFA and
cancer risk [25]
No association between fish
or FO intake and cancer
risk [107]
Inverse association between
higher fish intake and risk
of cancer death [108]
No association between
erythrocyte membrane
EPA, DPA, or DHA and
total or
advanced/high-grade
cancer risk [109]
Inverse association between
FO intake and risk of
advanced cancer later life
[110]
No association between
serum EPA or DHA and
cancer risk in male smokers
[111]
Inverse association between
DPA level and total risk of
cancer [112, 113]
No association between
omega-3 PUFA intake and
PSA level [114]
Positive association
between EPA or DHA and
high-grade cancer [112, 113]
No association between
DHA level and risk of
cancer at any stages [105]
No association between
total serum PL omega-3
PUFA and cancer risk [115]
Meta-analyses
Inverse association between
fish intake and prostate
cancer-specific mortality
[116]
No association between FO
intake or EPA/DHA blood
level and cancer risk [117]
FO: fish oil; PL: phospholipids; PSA: prostate-specific antigen.
As mentioned above, in their recently published case-
control substudy from the SELECT study population Brasky
et al. [25] reported a positive association between high plasma
phospholipid omega-3 PUFA content at baseline and prostate
cancer. However, we should underline that the SELECT trial
was not addressing omega-3 PUFA supplementation for the
prevention of prostate cancer. The authors used data from
two case-control studies [25, 202], nested within intervention
trials which were unrelated to eating fish or taking omega-
3 supplements. In these studies, the dietary intake of fish or
omega-3 had not been analyzed, neither advice was given
to eat fish or take fish oil supplement [194]. Moreover,
omega-3 PUFA were measured only once at baseline and
only in plasma phospholipids [27] and not in red blood cell
membranes. In fact, it has been suggested that evaluating the
“omega-3 index,” that is, the incorporation of omega-3 PUFA
in erythrocytes, may better reflect the omega-3 PUFA status
of the subjects [77, 78].
The current state of evidence for the effects of omega-3
PUFA in human studies regarding prostate cancer and the
contrasting outcomes have been summarized in Table 7, and
additional possible reasons for the controversies in the field
are reported in Section 6.
Overall, we can conclude that the literature on the role
of omega-3 PUFA in prostate cancer is remarkably consistent
among cell culture and animal studies, and controversies
came mostly from association studies in human populations.
However, the preventive effect of omega-3 PUFA on prostate
cancer is still uncertain, and the controversy will probably
remain until the mechanisms are clarified. However, while
current humandata are certainly not sufficient to recommend
omega-3 PUFA to prevent prostate cancer, they are also far
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from being sufficient to support a prostate cancer promoting
effect of these FA [188, 190, 191, 193, 203, 204].
6. Possible Reasons for Controversies
Several reasons may be responsible for the discrepancies
registered among the outcomes of human studies. First of all,
it should be considered that even though omega-3 PUFA can
be regarded as medication and high-dose preparations are
approved as prescription drugs in many parts of the world,
omega-3 PUFA are essential part of our diet.Their intake can
vary widely from population to population and even within
the same person, depending on actual dietary habits or short-
term dietary changes (eating seafood during vacations on
the coast). Often, the epidemiological observational studies,
particularly the early studies, refer to Food Frequency Ques-
tionnaire and Diet Records to establish fish consumption.
However, this methodology is prone to measurement errors
[205], and a low correlation coefficient (0.11–0.18) has been
shown to exist between fish intake frequency and direct
measurements of FA in patient samples [205, 206], even after
adjusting for confounding factors, such as age [207, 208].
A number of other variables may contribute to this scarce
correlation, such as the individual capacity to adsorb and
make the PUFAbioavailable at the serum level, the fat content
of the diet, or the omega-3/omega-6 PUFA dietary ratio.
Moreover, different methods are used to calculate dietary fats
or specific FA in the diets [209]. Often the questionnaires
refer only to fish servings per week, without considering the
serving size or the kind of fish consumed (lean fish or fatty
fish) [207]. It is known that there exists an extreme variability
in fish intake among populations, and if we consider the
amount of fish ingested by the “low fish consumers” among
the populations at high fish intake, it may correspond to or
be even higher than the amount consumed by the “high fish
consumers” in the populations at low fish intake. As a matter
of fact, positive association between dietary intake of omega-
3 PUFA and health effects has been registered mainly among
population eating fish at high levels [15]. Some intrinsic
weaknesses of questionnaire studies could thus be addressed
by actually measuring omega-3 PUFA in the participants.
Some more recent studies have directly evaluated the levels
of omega-3 PUFA in serum, in different plasmatic lipid
classes, or in erythrocytes [210–212]. Whereas it has been
argued that measuring the omega-3 PUFA level only in one
class of plasma lipids may be misleading [27], it has been
suggested that erythrocyte EPA and DHA content (named
“omega-3 index”)may better reflect the omega-3 PUFA status
of the subjects [77, 78]. This is because the plasma-based
measurements merely represent the short-term availability
of omega-3 PUFA, being susceptible to artificial elevation
following an acute omega-3 PUFA load [213]. Indeed, it has
been recently reported that an acute single dose (3.4–4 g/d) of
omega-3 PUFA, in the form of either prescriptionmedication
or dietary supplements, peaked plasma EPA + DHA levels
as early as 5 h after administration, whereas the EPA plus
DHA concentrations in erythrocyte membranes were only
increased by approximately 10 orders of magnitude less than
the concurrent plasma (3% versus 30%) from baseline at
24 h [214, 215]. Therefore, even if a single evaluation may
be confounding, since serum FA are powerfully affected
by feeding/fasting cycles and by the lipid content of the
last meal consumed [27], one possibility of overcoming the
discrepancies in omega-3 PUFA research is to call for actual
correlation of questionnaire-based calculations of omega-
3 PUFA intake with at least one actual measurement per
participant in order to obtain some biochemical information
regarding actual omega-3 PUFA levels.
Moreover, we ask if intervention studies administering
defined amounts of omega-3 PUFA may solve this problem.
At least these studies exactly define the amount of omega-3
PUFA administered. A rather big problem with these studies
is the big range of doses of omega-3 PUFA administered on
one hand and the variability of baseline diets on the other
hand. In order to understand discrepancies and problems of
omega-3 PUFA efficacy in intervention trials, we will have to
regard the omega-3 PUFA as parts of diet and component of
normal human body homeostasis.This is a concept obviously
radically different from synthetic drug studies and something
that has always to be taken into account when assessing
intervention studies. In such studies, the animals/subjects
have been treated with specific and controlled amounts of
omega-3 PUFA. But most of these studies neither established
baseline omega-3 PUFA body content in the participants nor
monitored omega-3 PUFA during the study, making proper
interpretation of the obtained results difficult. A recent study
properly addressing these issues was the Welcome Trial in
NASH patients, in which interpretation of the data focused
on the correlation of measured DHA enrichment with liver
fat content, as well as on pure ITT analysis of the treatment
group. It demonstrated a statistically significant linear corre-
lation between decreased liver fat content and increasedDHA
enrichment, but no significant effect in the ITT treatment
group analysis [64]. Therefore, as in observational studies,
intervention trials should perform biochemical analyses of
omega-3 PUFA content to (1) define baseline levels in the
different groups and (2) determine actual changes in the
different groups due to the treatment as compared to the
placebo group, where some of the participants might actually
contaminate the results by starting to consume a high fish diet
during the trial period.
Omega-3 PUFA dose is an issue as well. The omega-3
PUFA dose was very high in earlier animal studies, ranging
from 2.0 to 8.0 (EPA + DHA g/kg body weight/day in mice)
inmost cancer studies [216]. But even the lower doses used for
animals, after the interspecies conversion [217], appear rather
high for humans (about 10–20 g/day in a person weighing
70 kg). However, it is remarkable that, at least in the few
human interventional trials completed in the cancer field, the
preventive effects were noticed with doses of only 2.0 g/day
(corresponding to about 0.03 g/kg body weight in a person
weighing 70 kg) [85, 91, 218, 219]. The positive anticancer
effects were accompanied (if evaluated) by a comparable
increase (ranging from 2-3- to 5-fold) in omega-3 PUFA
incorporation in plasma or tissue lipids, in both animals and
humans [216].
The source of the omega-3 PUFA ingested may also be
important. Interventional studies often use highly purified
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omega-3 PUFA. They may help to obtain more clear results
than the use of fish/FO, since fish also represents a good
source of selenium, various vitamins, taurine, and other com-
pounds that have been shown to possess potential protective
effects [220–222]. Moreover, high levels of contaminant and
dangerous agents may accumulate in fish tissues and fat.
Some of these agents (such as organochlorine pesticides or
Hg) are environment-derived and may be present in the
tissues of both farmed and wild fish (especially predator
fish). Moreover, other cytotoxic and carcinogenic products
of omega-3 PUFA may be formed in fish after cooking them
at extremely high temperature (by broiling/frying fish) or
preserving them by smoking procedures [26]. The omega-
3 PUFA oxidative products may be formed in omega-3
fortified food and in omega-3 supplements that do not
contain adequate levels of antioxidants and are stored at room
temperature for a long time [26]. Furthermore, the general
composition of the diet has to be taken into account, since the
effect of increased omega-3 PUFA uptake might be different
in the context of a high-carbohydrate diet as compared to a
high-fat diet. This might change absorption and processing
of the omega-3 PUFA and thus affect actual concentrations in
the body. In addition, the highly critical factor omega-6 PUFA
and the actual omega-6/omega-3 PUFA dietary ratio may
deeply alter the effects of omega-3 PUFA supplementation.
Considerable attention has been drawn recently to the
possibility that interactions may exist between the subject
genetic background and the effects of nutritional interven-
tions [223, 224]. Different observational studies have already
demonstrated that the inverse association between omega-
3 PUFA intake or plasma/tissue enrichment and the risk
of several diseases may be limited only to subpopulations
possessing specific genetic features/signatures [99, 106, 225–
230]. Genetic differences or gender-specific effects [97]might
be due to differences in the expression of effector proteins for
the omega-3 PUFAand their lipidmediator products, but also
due to differences in enzymes of lipid metabolism that might
lead to differences in the processing of the omega-3 PUFA
in the body. Both issues, assessing the source of omega-3
PUFA and dietary composition as well as genetic background
affecting handling of the omega-3 PUFA, also call for more
measurements to better understand controversial results.
7. Conclusions
Our review of the omega-3 PUFA research literature prompts
us to conclude that the animal and in vitro data have
been remarkably consistent in showing health benefits,
particularly through mechanisms dampening inflammation
and proliferation in different tissues. These results have
established potential protective effects of omega-3 PUFA in
diseases ranging from cardiac arrhythmia and inflammatory
conditions (atherosclerosis to airway inflammation, colitis,
pancreatitis, steatohepatitis, arthritis, etc.) to tumorigenesis
(particularly colon and liver tumors, but also breast and
prostate cancer). On the other hand, the outcomes of human
studies have been so far quite controversial. Therefore, in
order to shed more light on this point and better understand
if the divergences were ascribable to possible methodological
weaknesses in human studies or, alternatively, to different
responses of human cells/tissues to the incorporation of
omega-3 as compared to those of laboratory animal species,
it is suggested that all future studies in this field should
perform blood FA measurements in trial participants. These
evaluations should be preferably performed in blood cells,
and, whenever possible, at baseline as well as at different
time-points during the study. This procedure would also be
extremely helpful to (1) monitor the effect of the huge omega-
3 PUFA supplement industry in the western world on omega-
3 PUFA content in humans, (2) understand the effect of
other FA in the context of omega-3 PUFA interventions, and
(3) recognize variations in individual responses to omega-3
PUFA supplementation.
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